Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach.

Date publication

mars 2023

Journal

Rheumatology (Oxford, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DUMORTIER Hélène , Pr GOTTENBERG Jacques-Eric

Tous les auteurs :
Felten R, Ye T, Schleiss C, Schwikowski B, Sibilia J, Monneaux F, Dumortier H, Jonsson R, Lessard C, Ng F, Takeuchi T, Mariette X, Gottenberg JE

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36869684

Résumé

To date, no immunomodulatory drug has demonstrated its efficacy in primary Sjögren's syndrome (pSS). We sought to analyze potential commonalities between pSS transcriptomic signatures and signatures of various drugs or specific knock-in or knock-down genes.

Mots clés

Clue, Drug repurposing, Histone deacetylase inhibitors, Interferons, Sjögren’s syndrome, Therapeutics, Transcriptomic signature

Référence

Rheumatology (Oxford). 2023 03 3;: